Zhuhai Rundu Pharmaceutical (002923.SZ) Receives Marketing Approval for Besylate Cisatracurium Chemical Raw Drug

Stock News08-04

Zhuhai Rundu Pharmaceutical Co.,Ltd. (002923.SZ) announced that its wholly-owned subsidiary, Rundu Pharmaceutical (Jingmen) Co., Ltd. (referred to as "Rundu Jingmen"), has recently received the Chemical Raw Drug Marketing Application Approval Notice for Besylate Cisatracurium issued by the National Medical Products Administration.

This pharmaceutical product is indicated for surgical procedures and other therapeutic interventions in adults and pediatric patients aged 1 month and above, and may also be utilized in intensive care unit treatments for adults. The drug can serve as an adjuvant for general anesthesia or be employed in ICU settings for sedation purposes to achieve skeletal muscle relaxation, thereby facilitating endotracheal intubation and mechanical ventilation procedures.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1152718103?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-08-04 16:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1152718103","market":"us","top_or_hot":-1,"title":"Zhuhai Rundu Pharmaceutical (002923.SZ) Receives Marketing Approval for Besylate Cisatracurium Chemical Raw Drug","media":"Stock News","content":"<p>Zhuhai Rundu Pharmaceutical Co.,Ltd. (002923.SZ) announced that its wholly-owned subsidiary, Rundu Pharmaceutical (Jingmen) Co., Ltd. (referred to as \"Rundu Jingmen\"), has recently received the Chemical Raw Drug Marketing Application Approval Notice for Besylate Cisatracurium issued by the National Medical Products Administration.</p>\n<p>This pharmaceutical product is indicated for surgical procedures and other therapeutic interventions in adults and pediatric patients aged 1 month and above, and may also be utilized in intensive care unit treatments for adults. The drug can serve as an adjuvant for general anesthesia or be employed in ICU settings for sedation purposes to achieve skeletal muscle relaxation, thereby facilitating endotracheal intubation and mechanical ventilation procedures.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Zhuhai Rundu Pharmaceutical (002923.SZ) Receives Marketing Approval for Besylate Cisatracurium Chemical Raw Drug</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nZhuhai Rundu Pharmaceutical (002923.SZ) Receives Marketing Approval for Besylate Cisatracurium Chemical Raw Drug\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2025-08-04 16:00</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Zhuhai Rundu Pharmaceutical Co.,Ltd. (002923.SZ) announced that its wholly-owned subsidiary, Rundu Pharmaceutical (Jingmen) Co., Ltd. (referred to as \"Rundu Jingmen\"), has recently received the Chemical Raw Drug Marketing Application Approval Notice for Besylate Cisatracurium issued by the National Medical Products Administration.</p>\n<p>This pharmaceutical product is indicated for surgical procedures and other therapeutic interventions in adults and pediatric patients aged 1 month and above, and may also be utilized in intensive care unit treatments for adults. The drug can serve as an adjuvant for general anesthesia or be employed in ICU settings for sedation purposes to achieve skeletal muscle relaxation, thereby facilitating endotracheal intubation and mechanical ventilation procedures.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK0239","symbol_name":"医药制造","start_time":0,"source_url":"","article_id":"1152718103","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1152718103","pubTimestamp":1754294422,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Zhuhai Rundu Pharmaceutical Co.,Ltd. (002923.SZ) announced that its wholly-owned subsidiary, Rundu Pharmaceutical (Jingmen) Co., Ltd. (referred to as \"Rundu Jingmen\"), has recently received the...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK0239":"医药制造","002923":"润都股份"},"translate_title":"珠海润都制药（002923.SZ）苯磺酸顺阿曲库铵化学原料药获上市批件","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"002923":1},"content_text":"Zhuhai Rundu Pharmaceutical Co.,Ltd. (002923.SZ) announced that its wholly-owned subsidiary, Rundu Pharmaceutical (Jingmen) Co., Ltd. (referred to as \"Rundu Jingmen\"), has recently received the Chemical Raw Drug Marketing Application Approval Notice for Besylate Cisatracurium issued by the National Medical Products Administration.\nThis pharmaceutical product is indicated for surgical procedures and other therapeutic interventions in adults and pediatric patients aged 1 month and above, and may also be utilized in intensive care unit treatments for adults. The drug can serve as an adjuvant for general anesthesia or be employed in ICU settings for sedation purposes to achieve skeletal muscle relaxation, thereby facilitating endotracheal intubation and mechanical ventilation procedures.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1152718103","isCrawlerRequest":true}